New biomarker analyses from the phase 3 KEYNOTE-522 trial provide insights into the biological factors that may influence response to pembrolizumab plus chemotherapy in early-stage triple-negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback